Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesDividends payablesLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Oramed Pharmaceuticals (ORMP) Non-Current Deferred Tax Liability (2025)

Oramed Pharmaceuticals' Non-Current Deferred Tax Liability history spans 1 years, with the latest figure at $7.9 million for Q4 2025.

  • For Q4 2025, Non-Current Deferred Tax Liability changed N/A year-over-year to $7.9 million; the TTM value through Dec 2025 reached $7.9 million, changed N/A, while the annual FY2025 figure was $7.9 million, N/A changed from the prior year.
  • Non-Current Deferred Tax Liability reached $7.9 million in Q4 2025 per ORMP's latest filing, roughly flat from $7.9 million in the prior quarter.
  • In the past five years, Non-Current Deferred Tax Liability ranged from a high of $7.9 million in Q3 2025 to a low of $7.9 million in Q4 2025.